Cover Image
市場調查報告書

發熱性嗜中性白血球低下症:開發中產品分析

Febrile Neutropenia - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 251568
出版日期 內容資訊 英文 60 Pages
訂單完成後即時交付
價格
Back to Top
發熱性嗜中性白血球低下症:開發中產品分析 Febrile Neutropenia - Pipeline Review, H2 2016
出版日期: 2016年10月26日 內容資訊: 英文 60 Pages
簡介

發熱性嗜中性白血球低下症常有伴隨發燒,類似於其他染症的症狀,常見於血液中嗜中性白血球(某種白血球)異常低落的嗜中性白血球低下症患者。在骨髓抑制療法中常常會判斷為一般的化療併發症。主要的症狀有發燒、流感般症狀、發冷發抖、嚴重盜汗、噁心嘔吐、壓痛、充血、浮腫、頭痛、頭部僵硬等。

本報告提供發熱性嗜中性白血球低下症的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃相關資訊等,以及最新的新聞和發表。

簡介

  • 調查範圍

發熱性嗜中性白血球低下症概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

發熱性嗜中性白血球低下症:企業開發中的治療藥

發熱性嗜中性白血球低下症:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

發熱性嗜中性白血球低下症:企業開發中的產品

發熱性嗜中性白血球低下症的治療藥開發企業

  • Apotex Inc.
  • Biogenomics Limited
  • Coherus BioSciences, Inc.
  • Dr. Reddy's Laboratories Limited
  • Richter Gedeon Nyrt.
  • Sandoz International GmbH
  • Therapeutic Proteins International, LLC
  • USV Limited

發熱性嗜中性白血球低下症:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

發熱性嗜中性白血球低下症:最近的開發平台趨勢

發熱性嗜中性白血球低下症:暫停中的計劃

發熱性嗜中性白血球低下症:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8593IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Febrile Neutropenia - Pipeline Review, H2 2016, provides an overview of the Febrile Neutropenia (Hematological Disorders) pipeline landscape.

Febrile neutropenia can develop in any form of neutropenia, but is most generally recognized as a complication of chemotherapy when it is myelosuppressive (suppresses the bone marrow from producing blood cells). Symptoms include fever, flu-like symptoms, shaking chills, severe night sweats, nausea and vomiting, especially with fever, tenderness, redness, swelling, pain or discharge at the site of a catheter and headache or neck stiffness.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Febrile Neutropenia - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Febrile Neutropenia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Febrile Neutropenia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Febrile Neutropenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 5, 1, 1, 2, 2, 1 and 3 respectively for Febrile Neutropenia.

Febrile Neutropenia (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Febrile Neutropenia (Hematological Disorders).
  • The pipeline guide reviews pipeline therapeutics for Febrile Neutropenia (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Febrile Neutropenia (Hematological Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Febrile Neutropenia (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Febrile Neutropenia (Hematological Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Febrile Neutropenia (Hematological Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Febrile Neutropenia (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Febrile Neutropenia Overview
  • Therapeutics Development
    • Pipeline Products for Febrile Neutropenia - Overview
  • Febrile Neutropenia - Therapeutics under Development by Companies
  • Febrile Neutropenia - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Febrile Neutropenia - Products under Development by Companies
    • Febrile Neutropenia - Companies Involved in Therapeutics Development
    • Apotex Inc.
    • BeyondSpring Pharmaceuticals, Inc.
    • Biogenomics Limited
    • Coherus BioSciences, Inc.
    • Dr. Reddy's Laboratories Limited
    • Richter Gedeon Nyrt.
    • Sandoz International GmbH
    • Therapeutic Proteins International, LLC
    • USV Pvt Ltd
  • Febrile Neutropenia - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • EC-18 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • filgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • filgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • filgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • plinabulin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Febrile Neutropenia - Dormant Projects
  • Febrile Neutropenia - Product Development Milestones
    • Featured News & Press Releases
      • Jul 11, 2016: Coherus Announces Positive Topline Results For CHS-1701 (Pegfilgrastim Biosimilar Candidate) Pharmacokinetic And Pharmacodynamic Biosimilarity Study
      • Feb 11, 2016: Sandoz advances its biosimilars program with EMA acceptance of regulatory submission for biosimilar pegfilgrastim
      • Feb 01, 2016: Coherus Announces CHS-1701 (Neulasta Biosimilar) Met Both Primary Endpoints in Registration-Enabling Immunogenicity Study
      • Dec 21, 2015: Coherus BioSciences Signs Strategic Manufacturing Agreement With KBI Biopharma for Commercial Supply of CHS-1701
      • Dec 08, 2015: Coherus BioSciences Reports Update to CHS-1701 Program
      • Dec 08, 2015: EMA started the evaluation of Richter's marketing authorisation application for biosimilar pegfilgrastim
      • Nov 18, 2015: Regulatory submission for Sandoz' proposed biosimilar pegfilgrastim accepted by the FDA
      • Mar 17, 2015: Coherus Finalizes CHS-1701 BLA Enabling Clinical Program and Initiates Pivotal Pharmacokinetic and Pharmacodynamic Study
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Febrile Neutropenia, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Febrile Neutropenia - Pipeline by Apotex Inc., H2 2016
  • Febrile Neutropenia - Pipeline by BeyondSpring Pharmaceuticals, Inc., H2 2016
  • Febrile Neutropenia - Pipeline by Biogenomics Limited, H2 2016
  • Febrile Neutropenia - Pipeline by Coherus BioSciences, Inc., H2 2016
  • Febrile Neutropenia - Pipeline by Dr. Reddy's Laboratories Limited, H2 2016
  • Febrile Neutropenia - Pipeline by Richter Gedeon Nyrt., H2 2016
  • Febrile Neutropenia - Pipeline by Sandoz International GmbH, H2 2016
  • Febrile Neutropenia - Pipeline by Therapeutic Proteins International, LLC, H2 2016
  • Febrile Neutropenia - Pipeline by USV Pvt Ltd, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Febrile Neutropenia - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Febrile Neutropenia, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top